These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6987190)

  • 41. Alterations in host responsiveness in patients with prostatic cancer following cryosurgery or transurethral resection.
    Ablin RJ; Bruns GR; Guinan PD; Sadoughi N; Sheik HA; Bush IM
    Am Surg; 1977 Mar; 43(3):144-50. PubMed ID: 320926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cryosurgery and immunotherapy for prostatic cancer.
    Loening S; Lubaroff D
    Urol Clin North Am; 1984 May; 11(2):327-36. PubMed ID: 6203207
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rat prostate carcinoma 11095-A: profile of organ- and tumor-specific antigens.
    Lande IJ; Feldbush TL; Lubaroff DM; Bonney WW
    Natl Cancer Inst Monogr; 1978 Dec; (49):283-7. PubMed ID: 86165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Behavior of phosphatases and carcino-embryonal antigens in serum following specific immunotherapy of metastasizing prostatic cancers].
    Rothauge CF; Kraushaar J; Gutschank S; Weidner W; Krause W
    Helv Chir Acta; 1981 Aug; 48(3-4):453-8. PubMed ID: 7287484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Historical development and potential uses of tumor antigens as markers of human cancer growth.
    Gold P; Shuster J
    Cancer Res; 1980 Aug; 40(8 Pt 2):2973-6. PubMed ID: 6249494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy for prostate cancer.
    Fong L; Small EJ
    Curr Urol Rep; 2006 May; 7(3):239-46. PubMed ID: 16630528
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Possible suppression of host resistance by estrogen therapy for prostatic cancer.
    Ablin RJ
    Can Med Assoc J; 1976 Dec; 115(11):1082-4. PubMed ID: 1000436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor immunology and immunotherapy.
    Herberman RB
    Laryngoscope; 1977 May; 87(5 Pt 1):722-5. PubMed ID: 321899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunologic considerations of carcinoma of the prostate.
    Guinan P; Bush IM; Sadoughi N; Mallick K; Ablin RJ
    Prog Exp Tumor Res; 1974; 19():353-68. PubMed ID: 4216041
    [No Abstract]   [Full Text] [Related]  

  • 50. Cryosurgery in prostate carcinoma: clinical evidence of immunostimulation of host versus tumor.
    Gonder MJ
    Natl Cancer Inst Monogr; 1978 Dec; (49):369. PubMed ID: 748795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunology in the diagnosis of cancer].
    Oettgen HF
    Internist (Berl); 1975 May; 16(5):199-205. PubMed ID: 1097358
    [No Abstract]   [Full Text] [Related]  

  • 52. Tumour immunology and the gut.
    Calman KC
    Gut; 1975 Jun; 16(6):490-9. PubMed ID: 50255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cryosurgery of SV40 prostatic transplant tumors: tumor control, biochemical correlates and immunity.
    Neel HB; Ketcham AS; Hammond WG
    Int Surg; 1972 Jan; 57(1):61-6. PubMed ID: 4333505
    [No Abstract]   [Full Text] [Related]  

  • 54. [Tissue polypeptide antigen as a marker for prostatic neoplasms. Preliminary study].
    Ruibal A; Durán P; Ibarz L; Fraile M; Roca I; de Torres Mateos JA
    Arch Esp Urol; 1984; 37(5):399-403. PubMed ID: 6517625
    [No Abstract]   [Full Text] [Related]  

  • 55. Cell-mediated immune competence in patients with prostatic carcinoma.
    Stefani SS; Menon M; Canning JR; Clark SS
    J Urol; 1978 Oct; 120(4):431-4. PubMed ID: 702665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy and prostate cancer.
    Kaminski JM; Summers JB; Ward MB; Huber MR; Minev B
    Cancer Treat Rev; 2003 Jun; 29(3):199-209. PubMed ID: 12787714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunologic studies of normal, benign, and malignant human prostatic tissue.
    Ablin RJ
    Cancer; 1972 Jun; 29(6):1570-4. PubMed ID: 4624168
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. II. Effect of oestrogen, cryosurgery and transurethral resection on thymic-dependent lymphocytic blastogenesis.
    Ablin RJ; Guinan PD; Bruns GR; Sheik HI; Sadoughi N; Bush IM
    Urol Int; 1976; 31(5):383-400. PubMed ID: 1087494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Significance of carcinoembryonic antigen in prostatic cancer].
    Navío Niño S; Allona Almagro A; Jiménez Cruz JF; Romero Aguirre C
    Actas Urol Esp; 1983; 7(4):281-2. PubMed ID: 6624575
    [No Abstract]   [Full Text] [Related]  

  • 60. A status report: human prostatic carcinoma, with emphasis on potential for viral etiology.
    Zeigel RF; Arya SK; Horoszewicz JS; Carter WA
    Oncology; 1977; 34(1):29-44. PubMed ID: 194197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.